Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Optimi Health Corp C.OPTI

Alternate Symbol(s):  OPTHF

Optimi Health Corp. is an end-to-end drug researcher and formulator licensed by Health Canada to produce and supply, for clinical research purposes, psychedelic substances, such as 3,4-Methylenedioxymethamphetamine (MDMA), natural Manufacturing Practices (GMP)-grade psilocybin, as well as functional mushrooms that focus on the health and wellness markets. The Company produces scalable psychedelic formulations for transformational human experiences. Its products are grown and manufactured at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia. It is a supplier of drug and nutraceutical products. The Company works with customers, health food distributors, and drug developers, and patients regulated by Health Canada.


CSE:OPTI - Post by User

Post by GajjarDron Oct 12, 2022 4:01pm
258 Views
Post# 35020548

RE:RE:RE:Opti Made It's Run -- NEXT Silo Wellness

RE:RE:RE:Opti Made It's Run -- NEXT Silo Wellness
Investing News Network October 11, 2022 Silo Wellnesss (CSE:SILO,OTCQB:SILFF)acquisition of Toronto-based biotech firm Dyscovry Scienceprovides an opportunity for the company to expand into the pharmaceutical space and biotech research, said Bradley Dottin, founder and president of Dyscovry Science. Dyscovry has been focused on biosynthetic manufacturing of psilocybin and its derivatives targeting a physiological condition called irritable bowel syndrome, a common disorder in the gastrointestinal tract affecting up to 15 percent of the worlds population. Silo Wellness is a psychedelic wellness company focused on researching psilocybin and developing psychedelic wellness facilities in jurisdictions with no legal barriers. So what we bring here is threefold," Dottin said. "We have a biosynthetic pathway, which allows us to work towards the production of psilocybin. And we also have a therapeutic angle with an indication specifically for irritable bowel syndrome coming alongside. And those are the unique factors. On top of this we've structured collaborations and partnerships with strategic partners, including the Canadian federal government research labs, to allow us to push this agenda for combining our strength with a deep breadth of expertise on the other side, but more importantly, the design and approach of thinking downstream to ultimately be able to produce this in a large scale." Through research collaboration with Canadian government research laboratories, Dyscovry intends to develop a biotech process for the production of psilocybin and its potential molecule derivatives. This adds pharmaceutical research and development to Silos patent-pending metered dosing formulations.
CyberSecurity wrote:
What makes you so sure Gajjar?
GajjarDr wrote:
Was lucky to have got word of gem early June before stock picked up. Next in line; SILO WELLNESS add them to your Psychedelic watch list. greenmarketreport.com/oregons-silo-wellness-buys-dyscovry-science-to-aid-psychedelic-retreats/




<< Previous
Bullboard Posts
Next >>